# US 8,771,783 B2 · Implant and method for manufacturing same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,771,783 B2 - Document ID: US8771783B2 - Status: Granted - Kind: B2 - Application number: 12/940,980 - Filed: 2010-11-05 - Published: 2011-05-12 - Granted: 2014-07-08 - Earliest claimed: 2009-11-10 - Assignees: Biotronik Vi Patent AG - Applicants: Ullrich Bayer - Inventors: Ullrich Bayer - Web page: https://patentgrep.com/patent/US8771783B2 ## CPC - A61L 31/088: {Other specific inorganic materials not covered by A61L31/084 or A61L31/086} - A61L 31/022: {Metals or alloys} - A61L 31/082: {Inorganic materials} - A61L 31/10: Macromolecular materials - A61L 31/148: {Materials at least partially resorbable by the body} - A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} - A61L 2420/02: Methods for coating medical devices - A61L 2420/08: Coatings comprising two or more layers - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) ## Abstract An implant, in particular an intraluminal endoprosthesis, is provided having an implant body containing biodegradable metallic material, preferably iron. To accelerate the degradation, at least a portion of the surface of the implant body has a first coating formed from a composition containing at least one element selected from the group including strontium and calcium. An inexpensive method for manufacturing such an implant is also described. ## Claims ### Claim 1 A method for manufacturing an implant, in particular an intraluminal endoprosthesis, having an implant body containing biodegradable iron, comprising the following steps: a) providing the implant body; b) coating the implant body with a composition containing at least one element selected from the group consisting of strontium and calcium, whereby the coating in step b) is carried out by deposition from a gas phase; and c) implanting nitrogen ions in the coated implant body. ### Claim 2 (depends on 1) The method according to claim 1, further comprising the step of applying a coating containing an acid-degradable polymer to the coated implant body, wherein the acid degradable polymer contains a pharmaceutically active substance is selected from the group consisting of a calcium channel blocker, a lipid regulator, an immunosuppressant, a calcineurin inhibitor, an anti-inflammatory agent, an endothelium-forming agent, a cytostatic agent, and a vasodilator. ### Claim 3 (depends on 1) The method according to claim 1, further comprising the step of applying a coating containing an acid-degradable polymer to the coated implant body, wherein the acid degradable polymer contains a pharmaceutically active substance comprising paclitaxel or sirolimus. ### Claim 4 A method for manufacturing an implant, in particular an intraluminal endoprosthesis, having an implant body containing biodegradable iron, comprising the following steps: a) providing the implant body; b) coating the implant body with a composition containing at least one element selected from the group consisting of strontium and calcium, whereby the coating in step b) is carried out by deposition from a gas phase; and c) applying a coating containing an acid-degradable polymer to the coated implant body. ### Claim 5 (depends on 4) The method according to claim 4, wherein the polymer contains a pharmaceutically active substance. ### Claim 6 (depends on 5) The method according to claim 5, wherein the pharmaceutically active substance is selected from the group consisting of a calcium channel blocker, a lipid regulator, an immunosuppressant, a calcineurin inhibitor, an anti-inflammatory agent, an endothelium-forming agent, a cytostatic agent, and a vasodilator. ### Claim 7 (depends on 5) The method according to claim 5, wherein the pharmaceutically active substance comprises paclitaxel or sirolimus. ### Claim 8 (depends on 5) The method according to claim 5, wherein the pharmaceutically active substance is for the treatment of a condition selected from the group consisting of restenosis, inflammation, and vascular spasm. ### Claim 9 A method for manufacturing an implant, in particular an intraluminal endoprosthesis, having an implant body containing biodegradable iron, comprising the following steps: a) providing the implant body; and b) coating the implant body with a composition containing strontium, whereby the coating in step b) is carried out by deposition from a gas phase. ### Claim 10 (depends on 9) The method of claim 9, further comprising treating the coated implant to insert strontium ions into a lattice of the implant body. ### Claim 11 (depends on 9) The method according to claim 9, further comprising implanting nitrogen ions in the coated implant body. ### Claim 12 (depends on 9) The method according to claim 9, further comprising applying a coating containing an acid-degradable polymer to the coated implant body, wherein the acid degradable polymer contains a pharmaceutically active substance selected from the group consisting of a calcium channel blocker, a lipid regulator, an immunosuppressant, a calcineurin inhibitor, an anti-inflammatory agent, an endothelium-forming agent, a cytostatic agent, and a vasodilator. ### Claim 13 (depends on 9) The method according to claim 9, further comprising applying a coating containing an acid-degradable polymer to the coated implant body, wherein the acid degradable polymer contains a pharmaceutically active substance comprising paclitaxel or sirolimus. ### Claim 14 A method for manufacturing an implant, in particular an intraluminal endoprosthesis, having an implant body containing biodegradable iron, comprising the following steps: a) providing the implant body; b) coating the implant body with a composition containing at least one element selected from the group consisting of strontium and calcium, whereby the coating in step b) is carried out by deposition from a gas phase; and c) treating the coated implant to insert strontium ions or calcium ions into a lattice of the implant body. ### Claim 15 (depends on 14) The method according to claim 14, further comprising applying a coating containing an acid-degradable polymer to the coated implant body, wherein the acid degradable polymer contains a pharmaceutically active substance comprising paclitaxel or sirolimus.